Event-Driven Stocks

Anebulo Pharmaceuticals, Inc.

ANEBOTC

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 1 warningdetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue——————
Operating income−$9.2M−$8.3M−$11.8M−$6.8M−$3.6M—
Net income−$8.5M−$8.2M−$11.7M−$6.8M−$30.3M−$174,637
Total assets$12.1M$4.1M$11.7M$15.6M$21.7M$3.0M
Total liabilities$487,688$260,583$1.1M$512,531$241,633$223,865
Equity$11.7M$3.8M$10.6M$15.1M$21.4M−$171,137
EPS (diluted)$-0.25$-0.32$-0.47$0.29$-2.83—
Shares out.41.1M25.9M25.6M23.4M23.3M12.0M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
—
Net margin
—
Return on equity
−72.8%
Return on assets
−69.9%
Return on capital (ROCE)
—
Liabilities / assets
4.0%
Debt / equity
0.04×
Book value / share
$0.28
Revenue growth (YoY)
—
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Accruals / assets
−17.6%clean
Piotroski F-Score
3/6weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
59
/ 100
Profitability 0Growth n/aCatalyst 67Earnings quality 67Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 warning● 2 good
  • Negative operating cash flow
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 20265,7521.30.0%
Apr 30, 20265,7521.0-0.4%
Apr 15, 20265,7771.0-0.0%
Mar 31, 20265,7781.0-90.4%
Mar 13, 202660,3221.0-56.9%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (3)